SunRock is a biotech company devoted to the development of therapeutic antibodies against cancer.
SunRock Biopharma transforms academic knowledge into therapeutic solutions through a disruptive open-innovation methodology. The core activity of the company lies in the development of innovative antibodies against highly invasive tumors with an urgent clinical need in oncology.
SunRock Biopharma strives to become a worldwide key agent in immunotherapy for oncology, through identification, development and transfer of academic knowledge to the pharmaceutical industry.
SR Open Innovation Strategy
SunRock Biopharma follows a disruptive methodology for drug development based on an open innovation model. In collaboration with the main research centers and key opinion leaders of the biotechnology innovation area, SunRock identifies significant academic research results and completes their development up to Phase I of clinical trials.
In summary, SunRock transforms the academic knowledge into therapeutic solutions for complex currently unmet pathologies.